June 11, 2009 (FinancialWire) — Generex biotechnology Corp. (NASDAQ: GNBT) said data in respect of two of its products was presented at the American Diabetes Association’s (ADA’s) 69th Annual Scientific Sessions held in New Orleans June 5 - 9, 2009.

As part of the session on New Concepts on Insulin Delivery Applications, independent clinician Professor Paolo Pozzilli, Head of the Department of Diabetes and Endocrinology at University Campus Bio-Medico, Rome, Italy, made a podium presentation of his abstract entitled Buccal Spray Insulin for the Management of Post-Prandial Hyperglycaemia in Subjects with Impaired Glucose Tolerance.

Postprandial hyperglycaemia occurs as the consequence of a reduced early insulin response after a meal and has been linked with an increased risk of cardiovascular events and raised mortality risk. Subjects with PPHG often present with dyslipidaemia, hypertension, abdominal obesity, microalbuminuria, endothelial dysfunction and markers of inflammation.

“With the explosion in the number of people with diabetes and pre-diabetes, now estimated to be 43% of the United States population over the age of 20, effective intervention will be required to address the significant attendant cardiovascular risks in the coming years,” said Dr. Gerald Bernstein, the company’s vice-president for medical affairs. “These study results suggest that Generex Oral-lyn(tm) could play a valuable role in the treatment regimen.”

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.